01.2022

January 6, 2022
|In Portfolio news
|By Ventac Partners

Ventac Partners portfolio company Orbit Genomics announced it has received $3 million in funding to launch its first product, OrbiSeq™ – L, a lung cancer diagnostic test with lead investors NHH Ventures and New Horizon Health Ltd (6606-HK). The company is raising an additional $1 million to complete the $4 million round. It also entered into an exclusive licensing agreement with New Horizon Health Ltd to market Orbit Genomics’ products in Asia.” More information on this transaction is available at this link.